Nektar Therapeutics
(NASDAQ : NKTR)

( )
NKTR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.98%81.590.9%$637.74m
CELGCelgene Corporation
-0.88%135.961.1%$563.57m
AMGNAmgen Inc.
-1.16%184.121.1%$451.54m
BIIBBiogen Inc.
-0.63%342.421.2%$397.97m
REGNRegeneron Pharmaceuticals, Inc.
0.36%440.942.7%$313.46m
ALNYAlnylam Pharmaceuticals, Inc
-1.63%115.6310.7%$252.14m
VRTXVertex Pharmaceuticals Incorporated
-0.10%154.601.9%$218.27m
INCYIncyte Corporation
-0.76%114.272.5%$205.56m
ALXNAlexion Pharmaceuticals, Inc.
0.16%140.461.9%$180.37m
EXELExelixis, Inc.
-0.25%27.466.5%$136.95m
ILMNIllumina, Inc.
-0.21%205.183.5%$132.63m
BLUEBluebird Bio, Inc.
0.25%139.4517.3%$114.79m
BMRNBioMarin Pharmaceutical Inc.
-0.55%88.134.4%$113.12m
SRPTSarepta Therapeutics, Inc.
-1.36%50.7216.9%$105.98m
CLVSClovis Oncology, Inc.
-2.48%76.7716.5%$102.15m

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products contain drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. The company provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, CA.